A Patient Using Varenicline During Smoking Cessation and Diagnosed with Type 1 Diabetes: A Case Report
نویسندگان
چکیده
Varenicline is one of the treatment options in smoking cessation treatments. It known that varenicline can predispose to diabetes or trigger and negatively affect glucose control. This effect has been reported as "uncommon side effects, may up 1 person every 100 people". In present case; A 21-year-old male, nicotine-addicted patient presented with diagnosis Type Diabetes during use cessation. Clinicians providing counseling should be careful about effects varenicline.
منابع مشابه
Spontaneous Hemothorax in a Patient with Neurofibromatosis Type 1: A Case Report
Background: Neurofibromatosis type1 (NF-1) is a hereditary autosomal dominant disease that is accompanied by complications, such as benign and malignant tumors and vascular involvement, including pulmonary hypertension, artery stenosis, and pulmonary artery aneurysm. Spontaneous hemothorax is a rare and lethal complication of NF-1 due to vasculopathy as stenosis or aneurysmal modifications of l...
متن کاملSmoking cessation therapy with varenicline
Smoking cessation is the only available intervention proven to halt progression of chronic obstructive pulmonary disease (COPD). The authors discuss the current existing treatment modalities and the role of a newly approved agent, varenicline, in promotion of smoking cessation. Varenicline is a novel agent that is a centrally acting partial nicotinic acetylcholine receptor agonist. It has both ...
متن کاملVarenicline: for smoking cessation.
Varenicline, a partial agonist of alpha4beta2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and...
متن کاملVarenicline: a novel pharmacotherapy for smoking cessation.
Varenicline is an orally administered small molecule with partial agonist activity at the alpha4beta2 nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the European Medicines Agency of the EU in 2006 as an aid to smoking cessation. Subsequently, varenicline has been approved in over 80 other countries. Varenicline is almost entirely absorbed following oral admini...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Turkish journal of family medicine and primary care
سال: 2021
ISSN: ['1307-2048']
DOI: https://doi.org/10.21763/tjfmpc.779217